Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on ...

A 26-year-old male with ataxia-telangiectasia died with a gastric adenocarcinoma. Malignancy is a recognised complication of this condition, the majority of cases being reticuloendothelial. There have ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Ataxia-telangiectasia (A-T) remains an incurable disease with limited treatment options. The progression of clinical trials is hindered by the lack of diagnostic and disease progression biomarkers for ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

The Schmitt family is grateful for the resources through A-T Children’s Project, as well as the love and care at St. Jude’s, ...

announced the online publication of safety data from patients with Ataxia-Telangiectasia (A-T) treated with EryDex for a minimum of 24 months in Frontiers in Neurology. “A-T is a rare pediatric ...

The event brought together 300 researchers, clinicians, industry leaders, and entrepreneurs to highlight their work.

In this paper the authors have identified two new participants in the damage-response pathway, using cells from patients with ataxia-telangiectasia [AT], a disease characterized by hypersensitivity to ...

Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) is a neurodegenerative disorder that primarily affects male carriers of the FMR1 gene premutation, characterized by an expansion of CGG ...